USPTO serial 99663191
AQUACYS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- MICHOS, JOHN E
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with AQUACYS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christopher D Olszyk, Jr.
Christopher D Olszyk, Jr. Fox Rothschild LLP212 Carnegie Center, Suite 400Princeton, NJ 08540United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biologics, namely, antibodies and antibody conjugates for scientific purposes, other than for medical or veterinary purposes; Biologics, namely, antibody conjugates for use in the formation of nanoparticles, for scientific and medical research; Chemical substances for the formation of antibody conjugates for use in scientific and medical research; Diagnostic preparations for scientific and medical research use in the field of antibody conjugates for scientific and medical research; Biologics, namely, antibody conjugate preparations used to incorporate cysteines into an antibody, namely, protein arrays and nucleotide arrays for scientific and medical research; Biologics, namely, antibodies incorporating engineered cysteines for use in conjugating cysteine reactive small and large molecules, resulting in conjugates with improved hydrophilicity, for scientific and medical research; Biologics, namely, antibodies incorporating engineered cysteines for use in conjugating cysteine reactive small and large molecules, for scientific and medical research; Chemical, biochemical and biological reagents for scientific or medical research use | ACTIVE | — |
| 005 | Diagnostic preparations, namely, antibodies incorporating engineered cysteines for use in conjugating cysteine reactive small and large molecules, for medical diagnosis and treatment purposes; Diagnostic preparations, namely, antibodies incorporating engineered cysteines for use in conjugating cysteine reactive small and large molecules, resulting in conjugates with improved hydrophilicity, for medical diagnosis and treatment purposes; Diagnostic preparations, namely, antibodies used to incorporate cysteines into an antibody, namely protein arrays, for medical diagnosis and treatment purposes; Delivery agents for antibodies, namely, drug delivery agents in the form of antibody conjugates that facilitate the delivery and action of medical preparations; Diagnostic preparations, namely, antibody conjugates for medical diagnosis and treatment in the fields of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders; Chemical, biological and biochemical preparations for medical and pharmaceutical use, namely, antibody conjugates for medical diagnosis and treatment in the fields of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders; Pharmaceutical preparations, namely antibody conjugates, for use in the diagnosis and treatment of diseases, namely, cancer, inflammatory disease, infectious disease and neurologic diseases and disorders; Diagnostic preparations featuring large and small molecules, namely, reagents, antibody fragments, antibodies, all intended for use in medical diagnosis and disease treatment; Pharmaceutical preparations and diagnostic preparations, namely, antibodies, antibody conjugates and active principles for medical diagnosis and disease treatment of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders. | ACTIVE | — |
| 042 | Research and development of antibody conjugates; Scientific research for medical purposes in the field of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders; Research and development services in the field of antibodies; Scientific and technological services and research relating thereto, namely, scientific research, analysis and testing in the fields of antibody conjugates; Antibody engineering; Custom design and engineering of antibodies; Research and development of pharmaceuticals for the treatment of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Research, development and establishment of testing specifications and procedures in the fields of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders research, diagnosis and treatment; Providing scientific research information in the fields of cancer, inflammatory disease, infectious disease and neurologic diseases and disorders research, diagnosis and treatment | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Aarvik Therapeutics, Inc.
- Other trademarks owned by Aarvik Therapeutics, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named AQUACYS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 13, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 13, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 7, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 15, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 10, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 10, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 10, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 12, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 12, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 12, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 10, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 22, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 20, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 20, 2026 | NWAP | NEW APPLICATION ENTERED | — |